CA2499817A1 - Derives comprenant des sterols et/ou des stanols et des classes specifiques d'agents anti-inflammatoires, et utilisation desdits derives pour le traitement ou la prevention de maladies cardiovasculaires - Google Patents

Derives comprenant des sterols et/ou des stanols et des classes specifiques d'agents anti-inflammatoires, et utilisation desdits derives pour le traitement ou la prevention de maladies cardiovasculaires Download PDF

Info

Publication number
CA2499817A1
CA2499817A1 CA002499817A CA2499817A CA2499817A1 CA 2499817 A1 CA2499817 A1 CA 2499817A1 CA 002499817 A CA002499817 A CA 002499817A CA 2499817 A CA2499817 A CA 2499817A CA 2499817 A1 CA2499817 A1 CA 2499817A1
Authority
CA
Canada
Prior art keywords
compound
group
acid
acids
inflammation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002499817A
Other languages
English (en)
Inventor
James P. Kutney
P. Haydn Pritchard
Yangbing Ding
Kishor M. Wasan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Forbes Medi-Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/255,558 external-priority patent/US20040236125A1/en
Application filed by Forbes Medi-Tech Inc filed Critical Forbes Medi-Tech Inc
Publication of CA2499817A1 publication Critical patent/CA2499817A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne, dans un aspect, de nouveaux dérivés, qui contiennent des stérols et/ou des stanols, ainsi qu'un AINS sélectionné dans le groupe constitué par des acides salicyliques et des acides arylalcanoïques, y compris des sels desdits dérivés; et présentent une ou plusieurs des formules suivantes: a) R¿2?-(CH¿2?)¿n?-CO-OR; b) R¿2?-R; c) R¿2?-CO-CO-OR; d) la formule (I), dans lesquelles R est un fragment de stérol ou de stanol; R¿2? est dérivé de l'acide salicylique ou de l'acide arylalcanoïque; et n=1-5. L'invention concerne également des compositions pharmaceutiques contenant un ou plusieurs de ces nouveaux dérivés; des méthodes de traitement ou de prévention de maladies cardiovasculaires ou de leurs affections sous-jacentes, y compris, mais pas exclusivement, l'athérosclérose, l'hypercholestérolémie, l'hyperlipidémie, l'hypertension, la thrombose, la coronaropathie; ou des méthodes de traitement et de réduction des inflammations, y compris l'inflammation des plaques coronaires, l'inflammation d'origine bactérienne, l'inflammation d'origine virale ou l'inflammation associée à la douleur aiguë ou à des interventions chirurgicales. Ces méthodes consistent à administrer à un animal, en particulier un être humain, une quantité non toxique, thérapeutiquement efficace d'un ou de plusieurs de ces composés, ou un sel biologiquement acceptable de ces composés.
CA002499817A 2002-09-25 2003-09-25 Derives comprenant des sterols et/ou des stanols et des classes specifiques d'agents anti-inflammatoires, et utilisation desdits derives pour le traitement ou la prevention de maladies cardiovasculaires Abandoned CA2499817A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10/255,558 US20040236125A1 (en) 2002-09-25 2002-09-25 Novel structures and compositions comprising sterols and/or stanols and specific classes of anti-inflammatory agents and use thereof in treating or preventing cardiovascular disease, its underlying conditions including hyperlipidemia and other disorders having inflammation as part of their aetiology or presentation
US10/255,558 2002-09-25
US66484303A 2003-09-16 2003-09-16
US10/664,843 2003-09-16
PCT/CA2003/001412 WO2004029068A1 (fr) 2002-09-25 2003-09-25 Derives comprenant des sterols et/ou des stanols et des classes specifiques d'agents anti-inflammatoires, et utilisation desdits derives pour le traitement ou la prevention de maladies cardiovasculaires

Publications (1)

Publication Number Publication Date
CA2499817A1 true CA2499817A1 (fr) 2004-04-08

Family

ID=32044971

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002499817A Abandoned CA2499817A1 (fr) 2002-09-25 2003-09-25 Derives comprenant des sterols et/ou des stanols et des classes specifiques d'agents anti-inflammatoires, et utilisation desdits derives pour le traitement ou la prevention de maladies cardiovasculaires

Country Status (10)

Country Link
EP (1) EP1556406A1 (fr)
JP (1) JP2006503840A (fr)
KR (1) KR20050084572A (fr)
CN (1) CN1684971A (fr)
AU (1) AU2003266885A1 (fr)
BR (1) BR0314700A (fr)
CA (1) CA2499817A1 (fr)
NO (1) NO20051932L (fr)
RU (1) RU2005112247A (fr)
WO (1) WO2004029068A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0513881D0 (en) 2005-07-06 2005-08-10 Btg Int Ltd Core 2 GLCNAC-T Inhibitors III
GB0329667D0 (en) 2003-12-22 2004-01-28 King S College London Core 2 GlcNAc-T inhibitor
US20080182801A1 (en) 2003-12-22 2008-07-31 Btg International Limited Core 2 glcnac-t inhibitors
DE102004008035A1 (de) * 2004-02-19 2005-09-08 Symrise Gmbh & Co. Kg Verwendung von (2-Hydroxyphenyl)-alkoholen sowie diese Verbindungen enthaltende kosmetische oder therapeutische Formulierungen
GB0513888D0 (en) 2005-07-06 2005-08-10 Btg Int Ltd Core 2 GLCNAC-T Inhibitors II
GB0513883D0 (en) 2005-07-06 2005-08-10 Btg Int Ltd Diagnosis of Atherosclerosis
DK2662382T3 (en) * 2012-05-10 2016-06-27 Beta Innov Sterol, MANUFACTURING METHOD THEREOF, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND USE THEREOF FOR THE TREATMENT OF MULTIPLE glioblastoma
CN104530167B (zh) * 2014-12-16 2016-02-24 吉林农业大学 水杨酸环戊烷并多氢菲酯a及其提取方法和药物用途
CN104434927A (zh) * 2014-12-16 2015-03-25 吉林农业大学 丙二酸双环戊烷并多氢菲酯b在制备降血压药物中的应用
CN111053741B (zh) * 2019-12-31 2021-09-28 江苏省中医院 一种用于治疗炎症性肠病的基于β-谷甾醇与5-ASA的口服多敏感胶束前药
CN114014905B (zh) * 2021-12-03 2023-07-21 浙江科技学院 靶向PPARγ的甘草次酸类衍生物及其制备方法和用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19518221A1 (de) * 1995-05-10 1996-11-14 Schering Ag Verwendung nichtsteroidaler Entzündungshemmer zur Verbesserung der physiologischen Verträglichkeit partikulärer pharmazeutischer Zubereitungen
AU4891699A (en) * 1998-07-20 2000-02-14 Forbes Medi-Tech Inc. Compositions comprising phytosterol, phytostanol or mixtures of both and omega-3fatty acids or derivatives thereof and use of the composition in treating or preventing cardiovascular disease and other disorders
ATE286064T1 (de) * 1999-06-21 2005-01-15 Forbes Medi Tech Inc Aromatische und heterozyklische derivate von phytosterolen und/oder phytostanolen zur behandlung von gefässkrankheiten
AU5383700A (en) * 1999-06-23 2001-01-31 Forbes Medi-Tech Inc. Conjugates of phytosterol or phytostanol with ascorbic acid and use thereof in treating or preventing cardiovascular disease
WO2001066560A2 (fr) * 2000-03-07 2001-09-13 Forbes Medi-Tech Inc. Nouveaux derives comprenant des phytosterols et/ou des phytostanols et des alpha-lipoiques et leur utilisation pour traiter ou prevenir les maladies cardio-vasculaires, leurs causes premieres et d'autres troubles
DE60125220T2 (de) * 2000-10-25 2007-04-12 Forbes Medi-Tech Inc., Vancouver Verbindungen,die ein phytosterol- und/oder ein phytostanolteil und ascorbinsäure enthalten und deren verwendung als gewichtsregulatoren
KR20040078683A (ko) * 2002-01-30 2004-09-10 파마시아 코포레이션 심혈관 질환의 예방 또는 치료를 위한 알도스테론 길항제및 비스테로이드 소염제의 조합 치료법

Also Published As

Publication number Publication date
KR20050084572A (ko) 2005-08-26
NO20051932L (no) 2005-04-20
BR0314700A (pt) 2005-07-26
WO2004029068A1 (fr) 2004-04-08
EP1556406A1 (fr) 2005-07-27
CN1684971A (zh) 2005-10-19
JP2006503840A (ja) 2006-02-02
RU2005112247A (ru) 2006-01-20
AU2003266885A1 (en) 2004-04-19

Similar Documents

Publication Publication Date Title
EP1004594B1 (fr) Utilisation d'esters de phytostérol et/ou phytostanol
ES2220986T5 (es) Composicion que comprende esteres de estanol vegetal y el uso del mismo para reducir el colesterol en el suero.
AU771960B2 (en) Compositions comprising phytosterol and/or phytostanol having enhanced solubility and dispersability
EP1227734B1 (fr) Compositions contenant des huiles ou des graisses comestibles ainsi que des phytost rols et/ou des phytostanols dissous
EP1189924B1 (fr) Conjugues de phytosterol ou de phytostanol et d'acide ascorbique, et leurs utilisations dans le traitement ou la prevention des maladies cardio-vasculaires
CA2332450A1 (fr) Compositions de phytosterol esterifie et hydrogene et leur utilisation dans des denrees alimentaires, des boissons, des produits pharmaceutiques, des aliments fonctionnels et analogue
WO2000015201A2 (fr) COMPOSITIONS COMPRENANT UN OU PLUSIEURS PHYTOSTEROLS, PHYTOSTANOLS, OU LEURS MELANGES, UN OU PLUSIEURS TOCOTRIENOLS, $G(ab, $G(b), $G(d) OU $G(g), OU LEURS DERIVES, UTILISATION DE CES COMPOSITIONS POUR TRAITER OU PREVENIR L'AFFECTION CARDIO-VASCULAIRE, SES ATTEINTES SOUS-JACENTES ET D'AUTRES ETATS PATHOLOGIQUES
CA2499817A1 (fr) Derives comprenant des sterols et/ou des stanols et des classes specifiques d'agents anti-inflammatoires, et utilisation desdits derives pour le traitement ou la prevention de maladies cardiovasculaires
EP1189923B1 (fr) Derives aromatiques et heterocycliques de phytosterols et/ou de phytostanols et leur utilisation dans le traitement ou la prevention de l'affection cardio-vasculaire
WO2001066560A2 (fr) Nouveaux derives comprenant des phytosterols et/ou des phytostanols et des alpha-lipoiques et leur utilisation pour traiter ou prevenir les maladies cardio-vasculaires, leurs causes premieres et d'autres troubles
NZ189297A (en) Pgs inhibitor containing sterol glycosides
AU2009202917B2 (en) Novel crystalline composites comprising phytosterols and phytostanols or derivatives thereof
US20040236125A1 (en) Novel structures and compositions comprising sterols and/or stanols and specific classes of anti-inflammatory agents and use thereof in treating or preventing cardiovascular disease, its underlying conditions including hyperlipidemia and other disorders having inflammation as part of their aetiology or presentation
JP2005535611A (ja) アスコルビン酸を伴った新規アンドロスタン及びアンドロステン誘導体並びに種々の病気、疾患及び障害の治療または予防におけるそれらの使用
RU2172629C2 (ru) Станоловая композиция и ее применение
AU2005211536B2 (en) Conjugates of phytosterol or phytostanol with ascorbic acid and use thereof in treating or preventing cardiovascular disease
CA2461136A1 (fr) Procede de reduction du transfert in vivo d'esters de cholesteryl e dont la mediation est assuree par la proteine de transfert des esters de cholesterol, entre les lipoproteines de haute densite (hdl) et les lipoproteines de basse densite (ldl)
AU2005202571A1 (en) Conjugates of phytosterol or phytostanol with ascorbic acid and use thereof in treating or preventing cardiovascular disease
AU2005202497A1 (en) Aromatic and heterocyclic derivatives of phytosterols and/or phytostanols for use in treating or preventing cardiovascular disease
AU2005209658A1 (en) Aromatic and heterocyclic derivatives of phytosterols and/or phytostanols for use in treating or preventing cardiovascular disease
AU2002328714A1 (en) A method of reducing the in vivo cholesterol ester transfer protein mediated transfer of cholesteryl esters between high density lipoproteins (HDL) and low density lipoproteins (LDL)

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued